Cancers (Oct 2020)
Efficacy and Safety of the Radiotherapy for Liver Cancer: Assessment of Local Controllability and Its Role in Multidisciplinary Therapy
- Marina Ohkoshi-Yamada,
- Kenya Kamimura,
- Osamu Shibata,
- Shinichi Morita,
- Motoki Kaidu,
- Toshimichi Nakano,
- Katsuya Maruyama,
- Atsushi Ota,
- Hirotake Saito,
- Nobuko Yamana,
- Tomoya Oshikane,
- Yukiyo Goto,
- Natsumi Yoshimura,
- Satoshi Tanabe,
- Hisashi Nakano,
- Madoka Sakai,
- Yuto Tanaka,
- Yohei Koseki,
- Yoshihisa Arao,
- Hiroyuki Abe,
- Toru Setsu,
- Akira Sakamaki,
- Takeshi Yokoo,
- Hiroteru Kamimura,
- Hidefumi Aoyama,
- Shuji Terai
Affiliations
- Marina Ohkoshi-Yamada
- Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, 1-757 Asahimachido-ri, Chuo-ku, Niigata, Niigata 951-8510, Japan
- Kenya Kamimura
- Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, 1-757 Asahimachido-ri, Chuo-ku, Niigata, Niigata 951-8510, Japan
- Osamu Shibata
- Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, 1-757 Asahimachido-ri, Chuo-ku, Niigata, Niigata 951-8510, Japan
- Shinichi Morita
- Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, 1-757 Asahimachido-ri, Chuo-ku, Niigata, Niigata 951-8510, Japan
- Motoki Kaidu
- Department of Radiology and Radiation Oncology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachido-ri, Chuo-ku, Niigata, Niigata 951-8510, Japan
- Toshimichi Nakano
- Department of Radiology and Radiation Oncology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachido-ri, Chuo-ku, Niigata, Niigata 951-8510, Japan
- Katsuya Maruyama
- Department of Radiology and Radiation Oncology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachido-ri, Chuo-ku, Niigata, Niigata 951-8510, Japan
- Atsushi Ota
- Department of Radiology and Radiation Oncology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachido-ri, Chuo-ku, Niigata, Niigata 951-8510, Japan
- Hirotake Saito
- Department of Radiology and Radiation Oncology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachido-ri, Chuo-ku, Niigata, Niigata 951-8510, Japan
- Nobuko Yamana
- Department of Radiology and Radiation Oncology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachido-ri, Chuo-ku, Niigata, Niigata 951-8510, Japan
- Tomoya Oshikane
- Department of Radiology and Radiation Oncology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachido-ri, Chuo-ku, Niigata, Niigata 951-8510, Japan
- Yukiyo Goto
- Department of Radiology and Radiation Oncology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachido-ri, Chuo-ku, Niigata, Niigata 951-8510, Japan
- Natsumi Yoshimura
- Department of Radiology and Radiation Oncology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachido-ri, Chuo-ku, Niigata, Niigata 951-8510, Japan
- Satoshi Tanabe
- Department of Radiology and Radiation Oncology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachido-ri, Chuo-ku, Niigata, Niigata 951-8510, Japan
- Hisashi Nakano
- Department of Radiology and Radiation Oncology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachido-ri, Chuo-ku, Niigata, Niigata 951-8510, Japan
- Madoka Sakai
- Department of Radiology and Radiation Oncology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachido-ri, Chuo-ku, Niigata, Niigata 951-8510, Japan
- Yuto Tanaka
- Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, 1-757 Asahimachido-ri, Chuo-ku, Niigata, Niigata 951-8510, Japan
- Yohei Koseki
- Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, 1-757 Asahimachido-ri, Chuo-ku, Niigata, Niigata 951-8510, Japan
- Yoshihisa Arao
- Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, 1-757 Asahimachido-ri, Chuo-ku, Niigata, Niigata 951-8510, Japan
- Hiroyuki Abe
- Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, 1-757 Asahimachido-ri, Chuo-ku, Niigata, Niigata 951-8510, Japan
- Toru Setsu
- Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, 1-757 Asahimachido-ri, Chuo-ku, Niigata, Niigata 951-8510, Japan
- Akira Sakamaki
- Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, 1-757 Asahimachido-ri, Chuo-ku, Niigata, Niigata 951-8510, Japan
- Takeshi Yokoo
- Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, 1-757 Asahimachido-ri, Chuo-ku, Niigata, Niigata 951-8510, Japan
- Hiroteru Kamimura
- Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, 1-757 Asahimachido-ri, Chuo-ku, Niigata, Niigata 951-8510, Japan
- Hidefumi Aoyama
- Department of Radiology and Radiation Oncology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachido-ri, Chuo-ku, Niigata, Niigata 951-8510, Japan
- Shuji Terai
- Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, 1-757 Asahimachido-ri, Chuo-ku, Niigata, Niigata 951-8510, Japan
- DOI
- https://doi.org/10.3390/cancers12102955
- Journal volume & issue
-
Vol. 12,
no. 10
p. 2955
Abstract
This study investigated the efficacy and safety of radiotherapy as part of multidisciplinary therapy for advanced hepatocellular carcinoma (HCC). Clinical data of 49 HCC patients treated with radiotherapy were assessed retrospectively. The efficacy of radiotherapy was assessed by progression-free survival, disease control rate, and overall survival. Safety was assessed by symptoms and hematological assay, and changes in hepatic reserve function were determined by Child–Pugh score and albumin–bilirubin (ALBI) score. Forty patients underwent curative radiotherapy, and nine patients with portal vein tumor thrombus (PVTT) underwent palliative radiotherapy as part of multidisciplinary therapy. Local disease control for curative therapy was 80.0% and stereotactic body radiotherapy was 86.7% which was greater than that of conventional radiotherapy (60.0%). Patients with PVTT had a median observation period of 651 days and 75% three-year survival when treated with multitherapy, including radiotherapy for palliative intent, transcatheter arterial chemoembolization, and administration of molecular targeted agents. No adverse events higher than grade 3 and no changes in the Child–Pugh score and ALBI score were seen. Radiotherapy is safe and effective for HCC treatment and can be a part of multidisciplinary therapy.
Keywords
- hepatocellular carcinoma
- radiotherapy
- Child–Pugh score
- ALBI score
- local disease control
- portal vein tumor thrombus
